Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein

Journal of Veterinary Pharmacology and Therapeutics

Volumn 36, Issue 6, 2013, Pages 583-587

  Zandvliet, M ^a   Teske, E ^a   Chapuis, T ^b   Fink Gremmels, J ^c   Schrickx, J A ^c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b B Science   (France)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MASITINIB; MULTIDRUG RESISTANCE PROTEIN;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOG; DRUG EFFICACY; IN VITRO STUDY; LYMPHOID CELL; LYMPHOID CELL LINE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

CANIS FAMILIARIS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLUORESCEINS; GENE EXPRESSION REGULATION; P-GLYCOPROTEIN; PROTEIN KINASE INHIBITORS; RHODAMINE 123; SUCCINIMIDES; THIAZOLES;

EID: 84887142290     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/jvp.12039     Document Type: Article

References (21)

1. Bellamy, F., Bader, T., Moussy, A. & Hermine, O. (2009) Pharmacokinetics of masitinib in cats. Veterinary Research Communications, 33, 831-837.
2. Bergman, P.J., Ogilvie, G.K. & Powers, B.E. (1996) Monoclonal antibody C219 immunohistochemistry against P-glycoprotein: sequential analysis and predictive ability in dogs with lymphoma. Journal of Veterinary Internal Medicine, 10, 354-359.
3. Gottesman, M.M. (2002) Mechanisms of cancer drug resistance. Annual Review of Medicine, 53, 615-627.
4. Gottesman, M.M., Fojo, T. & Bates, S.E. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nature reviews. Cancer, 2, 48-58.
5. Hahn, K.A., Ogilvie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P.S., Kinet, J.P., Palmerini, F., Dubreuil, P., Moussy, A. & Hermine, O. (2008) Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine, 22, 1301-1309.
6. Hahn, K.A., Legendre, A.M., Shaw, N.G., Phillips, B., Ogilvie, G.K., Prescott, D.M., Atwater, S.W., Carreras, J.K., Lana, S.E., Ladue, T., Rusk, A., Kinet, J.P., Dubreuil, P., Moussy, A. & Hermine, O. (2010) Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. American Journal of Veterinary Research, 71, 1354-1361.
7. Hegedus, C., Ozvegy-Laczka, C., Apati, A., Magocsi, M., Nemet, K., Orfi, L., Keri, G., Katona, M., Takats, Z., Varadi, A., Szakacs, G. & Sarkadi, B. (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. British Journal of Pharmacology, 158, 1153-1164.
8. Hogan, L.E., Meyer, J.A., Yang, J., Wang, J., Wong, N., Yang, W., Condos, G., Hunger, S.P., Raetz, E., Saffery, R., Relling, M.V., Bhojwani, D., Morrison, D.J. & Carroll, W.L. (2011) Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood, 118, 5218-5226.
9. Honjo, Y., Hrycyna, C.A., Yan, Q.W., Medina-Pérez, W.Y., Robey, R.W., van de Laar, A., Litman, T., Dean, M. & Bates, S.E. (2001) Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Research, 61, 6635-6639.
10. Honscha, K.U., Schirmer, A., Reischauer, A., Schoon, H.A., Einspanier, A. & Gabel, G. (2009) Expression of ABC-transport proteins in canine mammary cancer: consequences for chemotherapy. Reproduction in domestic animals, 44 (Suppl. 2), 218-223.
11. Jovelet, C., Benard, J., Forestier, F., Farinotti, R., Bidart, J.M. & Gil, S. (2012) Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin. European Journal of Pharmaceutical Sciences, 46, 484-491.
12. van der Kolk, D.M., de Vries, E.G., Koning, J.A., van den Berg, E., Muller, M. & Vellenga, E. (1998) Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clinical Cancer Research, 4, 1727-1736.
13. Lee, J.J., Hughes, C.S., Fine, R.L. & Page, R.L. (1996) P-glycoprotein expression in canine lymphoma: a relevant, intermediate model of multidrug resistance. Cancer, 77, 1892-1898.
14. Leier, I., Jedlitschky, G., Buchholz, U., Cole, S.P., Deeley, R.G. & Keppler, D. (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. Journal of Biological Chemistry, 269, 27807-27810.
15. Nakaichi, M., Taura, Y., Kanki, M., Mamba, K., Momoi, Y., Tsujimoto, H. & Nakama, S. (1996) Establishment and characterization of a new canine B-cell leukemia cell line. The Journal of Veterinary Medical Science, 58, 469-471.
16. van der Sandt, I.C., Blom-Roosemalen, M.C., de Boer, A.G. & Breimer, D.D. (2000) Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. European Journal of Pharmaceutical Sciences, 11, 207-214.
17. Shukla, S., Robey, R.W., Bates, S.E. & Ambudkar, S.V. (2009) Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 37, 359-365.
18. Steingold, S.F., Sharp, N.J., McGahan, M.C., Hughes, C.S., Dunn, S.E. & Page, R.L. (1998) Characterization of canine MDR1 mRNA: its abundance in drug resistant cell lines and in vivo. Anticancer Research, 18, 393-400.
19. Thamm, D.H., Rose, B., Kow, K., Humbert, M., Mansfield, C.D., Moussy, A., Hermine, O. & Dubreuil, P. (2012) Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. Veterinary Journal, 191, 131-134.
20. Wong, S. & Witte, O.N. (2004) The BCR-ABL story: bench to bedside and back. Annual Review of Immunology, 22, 247-306.
21. Zhou, W.J., Zhang, X., Cheng, C., Wang, F., Wang, X.K., Liang, Y.J., Kin Wah To, K., Zhou, W., Huang, H.B. & Fu, L.W. (2012) Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. British Journal of Pharmacology, 166, 1669-1683.